DYNAMIS PHARMACEUTICALS

Dynamis Pharmaceuticals, Inc. is a biopharma company that is developing proprietary small molecule drugs to treat chronic inflammatory diseases. Its proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone, that stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress and a cascade of inflammatory cytokines.